Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202505082 A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Sequential Treatment with P1101 and P1801 in Patients with Advanced Solid Tumors New Drug Phase Ⅰ
N202505092 Application of innovative method to profile the immune phenotype of sepsis-induced kidney injury New Medical Device NA
N202505129 AI-Assisted Abdominal CT Diagnostic Software for Pneumoperitoneum Risk Assessment New Medical Device NA
N202505138 A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low-Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event New Drug Phase Ⅲ
N202505161 Development and Application of an Innovative Non-Invasive Deep Brain Stimulation Technology for Parkinson’s Disease New Medical Device NA
N202506006 A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors New Drug Phase Ⅱ
N202506017 A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-agent Chemotherapy as Third-line Treatment in Subjects with Advanced / Metastatic Non- Small Cell Lung Cancer (NSCLC) New Drug Phase Ⅲ
N202506018 A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) New Drug Phase Ⅱ
1 2 25 26 27 28 29 30 31 51 52 / 52

TOP